Tardigrade Protein Could Soon Make Cancer Patients More Radiation Proof
When people undergo radiotherapy for cancer, it's not just the tumor that suffers. The radiation causes DNA breaks in healthy ...
层浪前沿|FongCyte推动生物材料硫化镓在肿瘤协同治疗领域的创新应用
GaSₓ具有 “重编程” 和 “干扰” ...
AFP13 天
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment ...
The secondary endpoints include ORR per tumor volume score (TVS), active range of motion (ROM), physical function, stiffness, quality of life, and pain, all assessed at Week 25. This study consists of ...
News Medical on MSN7 天
FDA approves Romvimza for tenosynovial giant cell tumor (TGCT)
That study included 123 patients, 83 of whom got vimseltinib and 40 of whom got a placebo. The investigators reported that 67 ...
Managed Healthcare Executive13 天
FDA Approves Gomekli, First and Only NF1-PN Treatment for Both Children and Adults
Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult ...
Medindia7 天
FDA Approves Vimseltinib to Treat Tenosynovial Giant Cell Tumor
Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...
UroToday9 天
ASCO GU 2025: Impact of Baseline PSMA PET in Patients with mCRPC Starting First-Line ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...